RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Clearside Biomedical - Stock

Clearside Biomedical P/S 2024

Clearside Biomedical P/S

134.19

Ticker

CLSD

ISIN

US1850631045

WKN

A2ALP6

As of Jun 27, 2024, Clearside Biomedical's P/S ratio stood at 134.19, a 1,493.71% change from the 8.42 P/S ratio recorded in the previous year.

The Clearside Biomedical P/S history

Clearside Biomedical Aktienanalyse

What does Clearside Biomedical do?

Clearside Biomedical Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of eye diseases and other medical conditions. The company was founded in 2011 by an experienced team of researchers and developers and is based in Alpharetta, Georgia. Clearside Biomedical Inc's history can be traced back to the groundbreaking research of Professor Henry Edelhauser, a renowned ophthalmologist and leading expert in the field of ophthalmology. Professor Edelhauser had the idea that by injecting drugs directly into the eye, specifically into the back part of the eye, more effective treatment could be achieved. Together with his team, he developed an innovative method for injecting drugs into the vitreous humor of the eye, which Clearside Biomedical Inc uses in its work. The business model of Clearside Biomedical Inc is based on the development and commercialization of therapies that rely on the intravitreal injection of drugs into the eye. The goal is to deliver drugs more effectively and precisely to the site of action, thus increasing the effectiveness of the treatment. The company focuses on the treatment of diseases of the posterior segment of the eye, such as age-related macular degeneration, diabetic retinopathy, or retinal vein occlusions. The various divisions of Clearside Biomedical Inc include research and development, clinical trials, manufacturing and marketing of therapies, as well as marketing and sales. The company places great importance on collaboration with leading scientists and regulatory bodies to ensure the effectiveness and safety of their products. Clearside Biomedical Inc's products include various innovative therapies for intravitreal injection, such as the drug Zuprata. Zuprata is a steroid specifically developed for the treatment of diseases of the posterior segment of the eye and has high efficacy. The drug is injected directly into the vitreous humor of the eye and has the advantage of being longer-lasting than other steroids. Another product of Clearside Biomedical Inc is the CLS-TA implant. The implant is based on an innovative technology that allows for continuous delivery of drugs over a longer period of time. The implant is directly implanted into the posterior part of the eye and can help increase the efficacy of drugs and reduce the number of necessary injections. Clearside Biomedical Inc has made significant progress in recent years and has successfully conducted several clinical trials. In 2019, the company received approval from the US Food and Drug Administration (FDA) for the marketing of Zuprata for the treatment of macular edema associated with uveitis. Overall, Clearside Biomedical Inc has a promising future. The company relies on innovative technologies and close collaboration with leading experts in the field of ophthalmology to develop new therapies and provide patients with better treatment options. Clearside Biomedical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Clearside Biomedical's P/S Ratio

Clearside Biomedical's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Clearside Biomedical's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Clearside Biomedical's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Clearside Biomedical’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Clearside Biomedical Stock

What is the price-to-earnings ratio of Clearside Biomedical?

The price-earnings ratio of Clearside Biomedical is currently 134.19.

How has the price-earnings ratio of Clearside Biomedical changed compared to last year?

The price-to-earnings ratio of Clearside Biomedical has increased by 1,493.71% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Clearside Biomedical high compared to other companies?

Yes, the price-to-earnings ratio of Clearside Biomedical is high compared to other companies.

How does an increase in the price-earnings ratio of Clearside Biomedical affect the company?

An increase in the price-earnings ratio of Clearside Biomedical would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Clearside Biomedical affect the company?

A decrease in the price-earnings ratio of Clearside Biomedical would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Clearside Biomedical?

Some factors that influence the price-earnings ratio of Clearside Biomedical are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Clearside Biomedical pay?

Over the past 12 months, Clearside Biomedical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clearside Biomedical is expected to pay a dividend of 0 USD.

What is the dividend yield of Clearside Biomedical?

The current dividend yield of Clearside Biomedical is .

When does Clearside Biomedical pay dividends?

Clearside Biomedical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clearside Biomedical?

Clearside Biomedical paid dividends every year for the past 0 years.

What is the dividend of Clearside Biomedical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clearside Biomedical located?

Clearside Biomedical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clearside Biomedical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clearside Biomedical from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Clearside Biomedical pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Clearside Biomedical in the year 2023?

In the year 2023, Clearside Biomedical distributed 0 USD as dividends.

In which currency does Clearside Biomedical pay out the dividend?

The dividends of Clearside Biomedical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Clearside Biomedical

Our stock analysis for Clearside Biomedical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clearside Biomedical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.